Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Significant hair regrowth was achieved using 1mg finasteride and 5% topical minoxidil over 14 months, with only initial shedding and mild scalp irritation as side effects. Consistency and early treatment are recommended for optimal results.

A 30-year-old man saw improved hair density and texture after three months using Minoxidil, Finasteride, and ketoconazole shampoo, despite initial side effects. He experienced increased body hair and libido and is satisfied with the results despite the high cost in Turkey.

A user reported positive results after four months of using finasteride and topical minoxidil for hair loss, with no side effects. They also use ketoconazole shampoo, dermarolling, and rosemary spray.

The user is considering switching from Finasteride to Dutasteride for better hair regrowth, despite concerns about potential shedding and side effects. Opinions vary, with some suggesting the switch for stronger results and others advising caution due to possible side effects and the importance of consulting a doctor.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

Oral minoxidil is seen as more effective and convenient than topical minoxidil for hair regrowth, but it may cause heart-related risks. Users often combine it with finasteride or dutasteride, though some prefer topical treatments due to safety concerns.

Effective treatments for hair loss include finasteride, dutasteride, RU58841, and minoxidil. Starting treatment early is important, and users discuss different brands, forms, and side effects.

Stopping minoxidil and finasteride for three months caused significant hair loss. The user resumed treatment with 2.5mg oral minoxidil and 0.6mg finasteride and plans to update on progress in three months.

There is concern about a potential ban on finasteride in the EU, but many believe it is unlikely unless serious side effects are found. Users rely on finasteride for hair loss and other health benefits, and a petition has been created to oppose any restrictions.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

A 23-year-old male shared his 6-month hair loss progress using Minoxidil, Finasteride, Ketoconazole shampoo, microneedling, and vitamin supplements. He noticed hair loss at 19, which accelerated during the pandemic.

The conversation discusses the risks and methods of ingesting liquid minoxidil for hair loss. Concerns include dosing accuracy, safety of ingredients, and potential side effects compared to using oral minoxidil tablets.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

A potential breakthrough in hair loss treatment involves softening hair follicle stem cells, but its effectiveness in humans is uncertain. Users express skepticism, noting past successes in mice that haven't translated to human treatments.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

Scientists discover SCUBE3 molecule for potential baldness cure. Mice used in research for hair growth signaling.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.